PDYN Gene Spinocerebellar Ataxia Type 23 Autosomal Dominant NGS Genetic DNA Test
Comprehensive Genetic Testing for Hereditary Ataxia
The PDYN Gene Spinocerebellar Ataxia Type 23 Autosomal Dominant NGS Genetic DNA Test represents a cutting-edge diagnostic approach for identifying individuals at risk for this specific form of hereditary neurological disorder. Spinocerebellar ataxia type 23 is a rare autosomal dominant condition characterized by progressive degeneration of the cerebellum and spinal cord, leading to significant movement coordination challenges.
What This Test Measures and Detects
This advanced genetic test specifically targets mutations in the PDYN (prodynorphin) gene located on chromosome 20. The test utilizes next-generation sequencing (NGS) technology to comprehensively analyze the entire coding region of the PDYN gene, identifying:
- Point mutations and single nucleotide variants
- Small insertions and deletions
- Missense mutations affecting protein function
- Autosomal dominant inheritance patterns
- Pathogenic variants associated with SCA23
Who Should Consider This Genetic Test
This test is particularly recommended for individuals experiencing:
- Progressive balance difficulties and unsteady gait
- Coordination problems affecting daily activities
- Slurred speech or dysarthria
- Family history of spinocerebellar ataxia
- Unexplained neurological symptoms beginning in adulthood
- Early-onset movement disorders without clear diagnosis
- Individuals planning pregnancy with family history of ataxia
Clinical Benefits of PDYN Gene Testing
Undergoing this comprehensive genetic analysis provides numerous advantages:
- Accurate Diagnosis: Confirms or rules out SCA23 with high precision
- Family Planning Guidance: Provides crucial information for genetic counseling
- Treatment Direction: Helps neurologists develop targeted management strategies
- Prognostic Information: Offers insights into disease progression expectations
- Early Intervention: Enables proactive symptom management approaches
- Peace of Mind: Reduces diagnostic uncertainty for patients and families
Understanding Your Test Results
Your genetic test results will be carefully interpreted by our team of certified genetic counselors and neurologists:
- Positive Result: Indicates the presence of a pathogenic PDYN gene mutation confirming SCA23 diagnosis
- Negative Result: Suggests absence of known SCA23-causing mutations in the PDYN gene
- Variant of Uncertain Significance: Identifies genetic changes with unclear clinical implications requiring further evaluation
- Carrier Status: Determines inheritance risk for future generations
All results include comprehensive genetic counseling to ensure complete understanding and appropriate next steps.
Test Pricing Information
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $500 |
| Regular Price | $700 |
Nationwide Testing Availability
We proudly offer comprehensive genetic testing services across the United States with convenient locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more cities. Our state-of-the-art laboratories ensure consistent, reliable results regardless of your location.
Take Control of Your Neurological Health
Don’t let uncertainty about hereditary neurological conditions affect your quality of life. Our PDYN Gene Spinocerebellar Ataxia Type 23 test provides the clarity needed for informed healthcare decisions. With results typically available within 3-4 weeks and comprehensive pre-test genetic counseling included, you’ll receive the expert guidance necessary to understand your genetic profile.
Ready to schedule your genetic test? Contact our genetic counseling team today at +1(267) 388-9828 or book your appointment online. Take the first step toward understanding your neurological health and genetic inheritance patterns with confidence and professional support.
